Novavax, Inc. reported an insider ownership change for Richard J. Rodgers involving the company’s common stock, tied to director equity compensation rather than an open-market stock purchase or sale. The Form 4 was filed on June 23, 2026, and identifies June 18, 2026, as the reported transaction date. The filing describes new equity awards granted under Novavax’s Amended and Restated 2015 Stock Incentive Plan, as amended. Rodgers received a stock option grant dated June 18, 2026, with 100% of the shares subject to the option scheduled to vest on the first anniversary of the grant date, June 18, 2027, provided he continues to serve on the company’s Board of Directors through that vesting date. The excerpt does not provide the number of option shares, exercise price, transaction code, or post-transaction ownership amount. Rodgers also received restricted stock units, or RSUs, under the same incentive plan. Each RSU represents a contingent right to receive one share of Novavax common stock. Like the option grant, 100% of the RSUs from the June 18, 2026 grant are scheduled to vest on June 18, 2027, subject to continued board service through that date. The filing text provided does not include the RSU share count or a stated transaction price. The filing also notes a vesting event for a prior RSU award. RSUs granted on June 20, 2025 vested in full on the first anniversary of that grant date, subject to Rodgers’ continued service as a director. No sale of shares, tax withholding transaction, or open-market disposition is described in the supplied text. Overall, the filing reflects routine board compensation activity: new annual equity awards to a Novavax director and the vesting of a previous RSU grant. The document was signed on Rodgers’ behalf by Mark J. Casey, attorney-in-fact, on June 23, 2026.